Ocugen, Inc. (OCGN)
After hours:
| Previous close | 1.3300 |
| Open | 1.2900 |
| Bid | 1.2800 x 47300 |
| Ask | 1.2900 x 46000 |
| Day's range | 1.2700 - 1.3450 |
| 52-week range | 1.0900 - 4.5300 |
| Volume | |
| Avg. volume | 5,233,604 |
| Market cap | 282.364M |
| Beta (5Y monthly) | 3.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings date | 23 Feb 2023 - 27 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.33 |
- Motley Fool
1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell
Ocugen (NASDAQ: OCGN) soared into the spotlight -- and its stock soared too -- when it entered the COVID-19 vaccine race two years ago. Or has Ocugen left center stage for good? Let's consider one reason to buy Ocugen in 2023 -- and two reasons to sell.
- GlobeNewswire
Ocugen Appoints Quan A. Vu as Chief Business Officer
MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline. “Expanding Ocugen’s product portfolio and capabilities, in line w
- GlobeNewswire
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Dr. Musunuri and members of Ocugen’s executive tea
